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Lekarz Małgorzata Kurpaska jest absolwentką Wydziału Lekarskiego Uniwersytetu Medycznego w Lub-
linie. Obecnie odbywa szkolenie specjalizacyjne z chorób wewnętrznych w Klinice Kardiologii i Chorób 
Wewnętrznych Wojskowego Instytutu Medycznego w Warszawie pod kierownictwem dra hab. n. med. 
Pawła Krzesińskiego. Zainteresowania naukowe dr Kurpaski skupiają się wokół wydolności fizycznej oraz 
zastosowania nieinwazyjnych metod, takich jak kardiografia impedancyjna czy tonometria aplanacyjna, 
w monitorowaniu profilu hemodynamicznego w trakcie wysiłku fizycznego. Czas wolny wypełnia jej rodzina.
Abstract
Introduction. Individual variation of exercise tolerance may be clinically important even in asymptomatic patients with 
arterial hypertension (HTN). The aim of the study was to evaluate the effect of antihypertensive therapy on exercise 
capacity assessed by a 6-minute walk test (6-MWT) and its relation to selected clinical and hemodynamic parameters.
Material and methods. In a group of 111 hypertensive patients without symptoms of heart failure, the change in 6-MWT 
distance (d_6-MWT) after 12 months of antihypertensive therapy was assessed in relation to their clinical status and 
hemodynamic parameters, assessed by echocardiography, impedance cardiography, and applanation tonometry.
Results. In the overall study group, antihypertensive therapy was associated with a significant increase in the mean 
d_6-MWT (592.9 ± 72.8 vs 613.4 ± 66.0 m, p = 0.030). The change in d_6-MWT depended on baseline values, with 
the most significant improvement (mean by 63.4 m) observed in patients with initially lowest d_6-MWT (bottom quartile, 
< 530 m). No statistically significant correlations were found between d_6-MWT and changes in clinical and hemodyna-
mic parameters. However, trends were noted towards positive associations between d_6-MWT and an echocardiograp-
hic indicator of left ventricular filling pressure (E/e’), left ventricular ejection fraction, and stroke index.
Conclusions. Antihypertensive therapy improves exercise capacity in hypertensives with initially reduced exercise capa-
city, and this effect may be related to positive changes in the left ventricular systolic and diastolic function.
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Introduction
Unspecific reduction of exercise tolerance is a subjective 
symptom, often neglected by both patients and healthcare 
personnel. Reduced exercise capacity depends not only on 
the cardiovascular status but also constitutional factors, 
condition of the skeletal muscle, and respiratory function 
[1]. In patients with hypertension (HTN), progressive car-
diovascular dysfunction is a continuous process, and the 
importance of subclinical abnormalities is often undere-
stimated. Cardiac remodelling associated with increased 
blood pressure (BP) and arterial stiffness usually leads first 
to left ventricular diastolic dysfunction [1–3] and only at 
a more advanced stage to reduced left ventricular ejection 
fraction (LVEF) and overt heart failure [4, 5]. Apparently 
mild reduction of left ventricular compliance at rest may 
manifest with significant pressure overload of the pulmo-
nary circulation during exercise, limiting tolerance of the 
latter [2, 6].
It is thus worth looking for simple, non-invasive he-
modynamic assessment tools in patients with reduced 
exercise tolerance at the early stage of hypertensive heart 
disease that might provide data on the potential underlying 
pathomechanisms and would be useful for the monito-
ring of treatment effects. We have previously found that 
multiparameter assessment of the cardiovascular system 
function by echocardiography and impedance cardiography 
(ICG) may be useful for the identification of hemodynamic 
abnormalities associated with reduced exercise capacity 
[7]. Based on these findings, we hypothesized that these 
methods may also be useful to evaluate the relations 
between antihypertensive treatment-induced changes in 
the hemodynamic profile and exercise capacity evaluated 
by 6-minute walk test (6-MWT).
Thus, the aim of our study was to evaluate the effect of 
antihypertensive treatment on exercise capacity evaluated 




The study was conducted in 139 asymptomatic patients of 
both genders with untreated HTN (with elevated BP values 
for ≥ 3 months) at a moderate level of physical activity. The 
baseline characteristics of the study group are shown in 
Table 1. The exclusion criteria were: 1) confirmed secondary 
HTN; 2) confirmed stage 3 or higher chronic kidney disease 
(glomerular filtration rate [GFR] < 60 mL/min/1.73 m2 by 
the Modification of Diet in Renal Disease Study [MDRD] 
formula); 3) other severe concomitant conditions such as 
systolic heart failure, cardiomyopathy, significant arrhyth-
mia, significant valvular heart disease, chronic obstructive 
pulmonary disease, diabetes, polyneuropathy, and pe-
ripheral arterial disease; age younger than 18 or older 
than 75 years; 5) body mass index (BMI) above 40 kg/m2; 
6) mental disorders precluding adequate patient com-
pliance; and 7) cardiac rhythm other than sinus rhythm 
(including permanent cardiac pacing).
The study protocol was approved by the bioethics 
committee at the Military Institute of Medicine (Wojskowy 
Instytut Medyczny [WIM], approval No. 3/WIM/2008), and 
each patient gave a written consent for the study partici-
pation. The study was performed under a WIM statutory 
research project (ID 148) undertaken in the Department 
of Cardiology and Internal Medicine, Military Institute of 
Medicine, and registered in the ClinicalTrials.gov database 
(NCT01996085).
The effect of antihypertensive therapy was evalua-
ted in 111 subjects who attended the follow-up visit at 
12 months. The analysis included clinical examination 
and hemodynamic parameters evaluated noninvasively 
using echocardiography, ICG, and applanation tonometry.
Clinical examination
Clinical examination was conducted with a particular focus 
on the history of cardiovascular risk factors. The presence 
of metabolic syndrome was defined according to the current 
International Diabetes Federation (IDF) guidelines [8]. The 
final analysis included the change in resting heart rate (HR) 
[bpm], systolic blood pressure (SBP) [mm Hg], and diastolic 
blood pressure (DBP) [mm Hg].
Six-minute walk test
Exercise capacity was evaluated during 6-MWT. The pa-
tients had been instructed to walk as fast as they could 
Table 1. Baseline characteristics of the study group
Variable Study group (N = 139)
Age [years], mean ± SD 45.6 ± 10.3
Men, n [%] 96 (69.1)
Stage 1 HTN*, n [%] 112 (79.2)
Stage 2 HTN*, n [%] 27 (19.4)
SBP [mm Hg], mean ± SD 141 ± 13
DBP [mm Hg], mean ± SD 90 ± 9
HR [bpm], mean ± SD 72 ± 10
BMI [kg/m2], mean ± SD 29.0 ± 4.2
LVH, n [%] 15 (10.8)
LVDD, n [%] 35 (25.2)
MS, n [%] 81 (58.3)
*According to the 2013 European Society of Hypertension/European Society of Cardiology guide-
lines classification of hypertension (HTN) [9]; SD — standard deviation; SBP — systolic blood 
pressure; DBP — diastolic blood pressure; HR — heart rate; BMI — body mass index; LVH — left 
ventricular hypertrophy; LVDD — left ventricular diastolic dysfunction; MS — metabolic syndrome
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at a comfortable pace along a 25-meter-long corridor 
marked every 5 meters. The total distance covered over 
6 minutes was rounded to 5 meters. All patients were 
evaluated for dyspnoea, chest pain, and palpitation 
during the test.
Echocardiography
Echocardiographic examinations were performed using a Vi-
vid S6 system (GE Medical System, Wauwatosa, WI, USA). 
Evaluation included cardiac chamber size, left ventricular 
systolic and diastolic function, and valvular structure and 
function. Left ventricular hypertrophy (LVH) was diagnosed 
based on the evaluation of left ventricular mass (LVM) in-
dexed for body surface (left ventricular mass index [LVMI] 
> 95 g/m2 in women, > 115 g/m2 in men). Left ventricular 
mass was calculated using the following formula: LVM = 
0.8 × (1.04 × [LVEDD+ PWTd + SWTd]3 – [LVEDD]3) + 0.6 
[g], where LVEDD is left ventricular end-diastolic diameter 
[mm], PWTd is diastolic posterior wall thickness [mm], and 
SWTd is diastolic septal wall thickness [mm]. Measure-
ments of the variables required for calculation, i.e. LVEDD, 
PWTd, and SWTd, were made in the long-axis parasternal 
view in M-mode, guided by two-dimensional (2D) imaging. 
Left ventricular ejection fraction [%] was measured using 
the Simpson method.
Left ventricular diastolic dysfunction was diagnosed 
based on the current guidelines [9] as reported previously 
[7]. Mitral flow was evaluated by pulsed wave Doppler in 
the apical four-chamber view, with measurement of the E 
wave deceleration time [ms] and the early to atrial filling 
velocity ratio (E/A). Using tissue Doppler imaging (TDI), 
early diastolic mitral annulus velocity (e’) [cm/s] was me-
asured and the E/e’ ratio [cm/s] was calculated. In the 
apical 5-chamber view, simultaneous assessment of the 
aortic and mitral flow was possible, with calculation of the 
isovolumetric relaxation time (IVRT) [ms]. The following 
values were considered diagnostic for left ventricular 
diastolic dysfunction: left atrial dimension above 40 mm 
in men, above 38 mm in women, E/A ratio below 0.8, E 
wave deceleration time above 200 ms, IVRT equal to or 
greater than 100 ms, e’ below 8 cm/s, E/e’ ratio above 8. 
Only the mild form of left ventricular diastolic dysfunction, 
i.e. impaired relaxation, was found.
Impedance cardiography
Hemodynamic parameters were measured by ICG during 
a 10-minute resting examination in a supine position, using 
a Niccomo™ device (Medis, Ilmenau, Germany). The final 
analysis included the following parameters: stroke index (SI) 
[mL × m–2], cardiac index (CI) [mL × m–2 × min–1], systemic 
vascular resistance index (SVRI) [dyn × s × cm–5 × m2], total 
arterial compliance (TAC) [mL × mm Hg–1], velocity index 
(VI) [1000 × Z0 × s–1], acceleration index (ACI) [100 × Z0 
× s–2], and thoracic fluid content (TFC) [L × kΩ–1].
Central blood pressure measurement
Central BP was measured noninvasively by applanation 
tonometry (SphygmoCor PxAortic BP Profile System, AtCor 
Medical Pty Ltd, Australia). Measurements were performed 
at the left radial artery in a supine position using a mic-
romanometer (Millar Instruments, Houston, Texas, USA) 
following the resting ICG examination. SphygmoCor 2000 
software (version 7.01; AtCor Medical) was used for pulse 
wave analysis. The following parameters were analysed: 
central systolic blood pressure (CSBP) [mm Hg], central 
diastolic blood pressure (CDBP) [mm Hg]), central pulse 
pressure (CPP) [mm Hg], and augmentation index (AI) [%].
Drug treatment
Non-drug treatment was consistent with the current 2013 
European Society of Hypertension/European Society of 
Cardiology guidelines [10]. Drug treatment was based on 
the methods used in the FINEPATH study (NCT01996085) 
[11]. Patients received at least one of the following drugs: 
lisinopril (ACEI, angiotensin-converting enzyme inhibitor), 
telmisartan (ARB, angiotensin receptor blocker), hydrochlo-
rothiazide/indapamide (diuretic), metoprolol/nebivolol (BB, 
beta-blocker), amlodipine (CCB, calcium channel blocker).
Statistical analysis
Statistical analysis was performed using Microsoft Office 
Excel 2007 and Statistica 10.0 (StatSoft Inc.) software. 
Results were expressed as mean values ± standard de-
viation (SD) for quantitative variables and numbers and 
percentages for qualitative variables. Variable distribution 
was assessed visually and using the Kolmogorov-Smirnov 
test. Correlations were evaluated using the Pearson cor-
relation coefficient for normally distributed variables and 
the Spearman rank correlation coefficient for non-normally 
distributed variables.
Change in a variable (d) was calculated using the 
formula: change (d_[variable]) = value at 12 months 
(c_[variable]) – baseline value (b_[variable]).
First, the interquartile range of baseline 6-MWT (b_6-
-MWT) [7] was used to evaluate the effect of antihy-
pertensive treatment on the change in 6-MWT (d_6-
-MWT). Then, to differentiate between changes in clinical 
and hemodynamic parameters in relation to d_6-MWT, 
the interquartile range was calculated for that variable 
(Q1: < [–35] m; Q2: [–35] – [13] m; Q3: [14] – [73] m; 
Q4: > [73] m) and a comparative analysis was performed 
in quartile subgroups (ANOVA or Kruskal-Wallis tests de-
pending on variable distribution). P < 0.05 was considered 
statistically significant.
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Table 2. Parameters at baseline and after 12 months of antihypertensive therapy
Variable Mean Minimum Maximum Standard deviation
b_6-MWT [m] 592.9459 400.0000 750.0000 72.77410
c_6-MWT [m] 613.3514 415.0000 760.0000 65.99265
b_HR [bpm] 73.0463 49.0000 99.0000 10.64322
c_HR [bpm] 67.6937 46.0000 89.0000 8.53740
b_SBP [mm Hg] 141.0180 111.0000 180.0000 13.18469
b_DBP [mm Hg] 90.0088 62.0000 122.0000 9.42075
c_SBP [mm Hg] 120.1261 98.0000 157.0000 9.60314
c_DBP [mm Hg] 76.9730 55.0000 94.0000 7.38852
b_E/A [–] 1.0559 0.5500 2.1000 0.32890
c_E/A [–] 1.1609 0.5200 2.1400 0.34031
b_e’ [cm/s] 9.6132 4.0000 15.5000 2.64601
c_e’ [cm/s] 10.3364 5.0000 17.0000 2.44303
b_E/e’ [–] 7.1780 4.3000 13.0000 1.73839
c_E/e’ [–] 6.9757 4.0600 13.8000 1.76113
b_LVEF [%] 64.8818 56.0000 72.0000 3.18463
c_LVEF [%] 66.3545 59.0000 75.0000 3.24980
b_variable — baseline value; c_variable — value at 12 months of treatment; 6-MWT — 6-minute walk test; HR — heart rate; SBP — systolic blood pressure; DBP — diastolic blood pressure; e’ — peak mitral 
annular velocity; E/e’ — early mitral inflow velocity to mitral annular velocity ratio; E/A — early to atrial mitral inflow velocity ratio; LVEF — left ventricular ejection fraction
Results
Effect of treatment on 6-MWT distance
Final analysis included 111 patients who completed one 
year follow-up. Antihypertensive treatment was associated 
with a significant increase in the mean 6-MWT distance 
(592.9 ± 72.8 vs. 613.4 ± 66.0 m, p = 0.030) in the overall 
study group. A significant reduction was also seen in SBP 
(141.0 ± 13.2 vs. 120.1 ± 9.6 mm Hg, p < 0.00001), DBP 
(90.0 ± 9.4 vs. 77.0 ± 7.4 mm Hg, p < 0.0001), and HR 
(73.0 ± 10.6 vs. 67.7± 8.5 bpm, p = 0.00005; Table 2).
The change in 6-MWT distance was related to the base-
line 6-MWT distance (b_6-MWT). The largest improvement 
was seen in patients with the lowest 6-MWT distance at 
baseline (bottom b_6-MWT quartile, < 530 m), in contrast 
to those with the highest 6-MWT distance at baseline (up-
per b_6-MWT quartile, > 650 m, Figure 1). When individual 
changes were plotted (Figure 2), a highly consistent trend 
was seen for an improvement in 6-MWT distance in those 
in the bottom b_6-MWT quartile, while a reverse trend was 
seen in those in the upper b_6-MWT quartile.
Associations between 6-MWT distance 
change and changes in other parameters
We did not find any significant correlations between 
d_6-MWT and changes in other analysed clinical and 
hemodynamic variables (Table 3). However, trends were 
seen towards a positive association between d_6-MWT 
and a reduction in E/e’ and an increase in LVEF, SI, and 
TFC, as well as for a higher rate of metabolic syndrome 
in subjects with no improvement in 6-MWT distance. No 
significant differences in drug therapy were found between 
d_6-MWT quartiles.
Discussion
Our study findings confirm that effective antihypertensive 
treatment is associated with an increase in the mean 
6-MWT distance. This effect is most pronounced in subjects 
with most limited exercise capacity at baseline. Hemodyna-
mic evaluation at rest has a limited value regarding identi-
fication of hemodynamic determinants of the change in the 
mean 6-MWT distance. However, the observed trend for an 
association between improvement in exercise capacity and 
reduced left ventricular filling pressure and improved left 
ventricular systolic function seems promising.
An increase in 6-MWT distance related to BP lowering 
by various antihypertensive drug classes has been confir-
med in studies by other authors [12, 13]. Thus, variation in 
exercise capacity in patients with HTN is not an incidental 
finding, although these subjects often do not report other 
heart failure symptoms. The most significant improvement 
in 6-MWT distance observed in those with the worst exerci-
se tolerance at baseline confirms that by using an objective 
diagnostic tool, it is possible to identify asymptomatic 
(based on a subjective patient’s assessment) reduction 
in exercise capacity that may be favourably modified by 
a therapeutic intervention.
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In our study, we did not find differences between va-
rious drugs used. This may be related to the design of the 
study which evaluated an overall treatment effect and not 
particular drug classes. The observed worse treatment in 
subjects with metabolic syndrome may be related to con-
stitutional limitations and more advanced hemodynamic 
abnormalities at baseline [14, 15].
Despite multiparametric assessment of the hemo-
dynamic profile, we did not identify any predominant 
mechanism responsible for the observed improvement in 
exercise capacity. Based on our previous study, in which 
we showed an association between 6-MWT distance and 
elevated parameters of large vessel stiffness [7], we 
expected a more evident association between changes 
in 6-MWT distance and afterload changes (SVRI, TAC, 
AI). Nevertheless, the observed trends for an association 
between the increase in 6-MWT distance and reduction 
of an echocardiographic indicator of diastolic function 
(E/e’), increase in LVEF, and increase in SI by impedance 
cardiography is consistent with our knowledge regarding 
cardiovascular pathophysiology. Exercise capacity is 
related to ventricular-vascular coupling. During exerci-
se, blood flow in various vascular beds is redistributed 
towards skeletal muscle. Significant changes in vascular 
Figure 2A , B. Comparison of individual values of 6-minute walk test distance (6-MWT) in two extreme b_6-MWT quartiles: A. Bottom quartile; 
B. Upper quartile; b_6-MWT — baseline 6-MWT distance; c_6-MWT — 6-MWT distance after 12 months
A B
Figure 1A, B. Relation between the change in 6-minute walk test distance (d_6-MWT) and its baseline value (b_6-MWT): A. Scatter and 
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Table 3. Relations between the change in 6-minute walk test (6-MWT) distance and other variables
Variable 6-MWT (quartiles) Correlation variable  
vs. d_6-MWT
Q1 (N = 27) Q2 (N = 28) Q3 (N = 26) Q4 (N = 28) p (overall) R p (overall)
Demographic and clinical characteristics
Age [years] 46.0 ± 10.9 46.7 ± 11.5 48.3 ± 9.6 45.2 ± 8.6 0.722 0.02 0.861
Male gender 20 (71.4) 19 (65.5) 18 (69.2) 20 (71.4) 0.957 – –
BMI [kg/m2] 29.9 ± 3.7 28.9 ± 3.7 28.4 ± 4.3 28.8 ± 4.0 0.596 –0.09 0.360
MS 21 (75.0) 17 (58.6) 13 (50.0) 14 (50.0) 0.191 – –
Office measurements
d_HR [bpm] –3.6 ± 8.2 –4.9 ± 9.6 –7.4 ± 13.1 –6.0 ± 11.0 0.876 –0.08 0.427
d_SBP [mm Hg] –22.5 ± 14.2 –20.9 ± 12.6 –18.0 ± 13.1 –21.9 ± 14.1 0.667 0.02 0.800
d_DBP [mm Hg] –15.1 ± 8.9 –11.9 ± 10.6 –12.5 ± 8.3 12.6 ± 9.9 0.693 0.06 0.558
Echocardiography
d_LVEF [%] 1.3 ± 4.3 0.3 ± 4.2 2.3 ± 4.2 2.3 ± 3.8 0.245 0.14 0.155
d_E/A [–] 0.14 ± 0.34 0.10 ± 0.37 0.12 ± 0.23 0.05 ± 0.28 0.671 –0.03 0.759
d_e’ [cm/s] 0.74 ± 2.68 0.57 ± 2.56 1.17 ± 2.35 0.75 ± 2.66 0.854 0.01 0.958
d_E/e’ [–] –0.22 ± 1.65 0.11 ± 2.09 –0.28 ± 1.62 –0.84 ± 1.67 0.294 –0.13 0.171
Impedance cardiography
d_SI [mL/m2] 0.3 ± 8.3 1.8 ± 9.6 3.2 ± 7.9 3.6 ± 9.8 0.527 0.16 0.096
d_CI [mL/min/m2] –0.17 ± 0.47 –0.2 ± 0.56 –0.10 ± 0.51 –0.01 ± 0.41 0.623 0.07 0.473
d_SVRI [dyn × s/
cm5/m2]
–251 ± 342 –318 ± 494 –164 ± 506 –247 ± 319 0.615 0.04 0.653
d_ACI [100 × Z0/s2] 2.3 ± 22.3 0.1 ± 18.0 5.9 ± 16.6 5.2 ± 21.9 0.690 0.07 0.453
d_VI [1000 × Z0/s] 1.3 ± 10.0 0.2 ± 10.2 3.1 ± 8.8 3.7 ± 10.3 0.783 0.11 0.274
d_TAC [mL/mm Hg] 0.21 ± 0.57 0.39 ± 0.56 0.32 ± 0.61 0.39 ± 0.65 0.640 0.04 0.653
d_TFC [L/kOhm] –0.5 ± 3.2 –0.1 ± 3.4 0.1 ± 4.3 1.3 ± 3.6 0.251 0.19 0.052
Applanation tonometry
d_CSBP [mm Hg] –186 ± 15.9 –15.1 ± 12.9 –17.0 ± 14.3 –12.5 ± 14.4 0.429 0.12 0.202
d_CDBP [mm Hg] –14.4 ± 9.6 –10.2 ± 10.2 –12.4 ± 8.9 –10.4 ± 8.9 0.461 0.10 0.297
d_CPP [mm Hg] –4.2 ± 9.4 –4.9 ± 7.5 –4.6 ± 9.2 –2.5 ± 9.3 0.561 0.09 0.332
d_AI [%] –0.7 ± 12.2 –0.9 ± 7.7 –1.2 ± 11.9 2.4 ± 11.4 0.846 0.06 0.523
Drug therapy
ACEI 21 (77.8) 21 (75.0) 20 (80.0) 19 (67.9) 0.751 – –
ARB 2 (7.4) 4 (14.3) 2 (8.0) 5 (17.9) 0.581 – –
CCB 5 (18.5) 6 (21.4) 5 (20.0) 1 (3.6) 0.230 – –
BB 7 (25.9) 4 (14.3) 8 (32.0) 7 (25.0) 0.495 – –
Diuretic 7 (25.9) 8 (28.6) 9 (36.0) 9 (32.1) 0.872 – –
Data shown as mean values ± standard deviation (SD) or numbers (percentages); BMI — body mass index; MS — metabolic syndrome; d_HR — change in heart rate; d_SBP — change in systolic blood pres-
sure; d_DBP — change in diastolic blood pressure; LVEF — left ventricular ejection fraction; d_LVEF — change in left ventricular ejection fraction; d_e’ — change in peak mitral annular velocity; d_E/A — chan-
ge in the early to atrial mitral inflow velocity ratio; d_E/e’ — change in the early mitral inflow velocity to mitral annular velocity ratio; d_SI — change in the stroke index; d_CI — change in the cardiac index;  
d_SVRI — change in the systemic vascular resistance index; d_ACI — change in the acceleration index; d_VI — change in the velocity index; d_TAC — change in total arterial compliance; d_TFC — change in 
thoracic fluid content; d_CSBP — change in central systolic blood pressure; d_CDBP — change in central diastolic blood pressure; d_CPP — change in central pulse pressure; d_AI — change in the augmenta-
tion index; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; CCB — calcium channel blocker; BB — beta-blocker
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the competition effect (resulting in an increase in 6-MWT 
distance by 20–30%) [29] was eliminated by performing 
these examinations individually.
Study limitations
A limitation of our study was the size of the study group 
which may have resulted in no significance of the asso-
ciation between d_6-MWT and changes in the analyzed 
clinical and hemodynamic parameters. An analysis limited 
to subjects with hypertension and no concomitant condi-
tions has eliminated an effect of confounding factors but 
it also precludes direct generalization of the study findings 
to the general population. Due to a progressive nature of 
hypertensive heart disease, a more evident improvement 
in exercise tolerance might be expected during longer 
follow-up and in patients with stage 3 HTN at baseline. Of 
note, further studies with hemodynamic monitoring during 
exercise are needed to expand our knowledge regarding 
the mechanisms of the observed improvement in exercise 
capacity.
The authors believe, however, that the above limita-
tions have had no significant effect on the overall value 
of the study.
Conclusions
Antihypertensive treatment in patients with hypertension 
and no overt heart failure improves exercise tolerance. 
Particularly beneficial effects were observed in subjects 
with limited exercise capacity at baseline. Non-invasive 
tools to evaluate hemodynamic parameters, particularly 
echocardiography and impedance cardiography, are useful 
for the assessment of hemodynamic response to exercise, 
including when monitoring the effects of antihypertensive 
treatment.
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resistance lead to a reduction in afterload, allowing an 
increase in cardiac output [16]. In contrast, an increase in 
aortic and large vessel stiffness results in left ventricular 
pressure overload which precludes adequate adjustment 
of cardiac output to match exercise-induced requirements 
[17]. In several previous studies, a significant inverse 
correlation was shown between markers of vascular 
stiffness (e.g., pulse wave velocity) with peak oxygen 
consumption (peakVO2) and 6-MWT distance [18–20]. 
With BP reduction, afterload is reduced and blood is 
ejected at a higher velocity from the left ventricle to 
a more compliant vascular system. Ultimately, more blood 
is ejected (an increase in SI) which results in a reduced 
end-systolic volume (ESV). In turn, lower ESV allows for 
an increased volume reservoir for venous return and thus 
left ventricular filling pressure is reduced [16]. Our study 
findings support the notion that treatment that aims to 
normalize vascular stiffness, left ventricular diastolic 
function, and increased left ventricular mass may be of 
no less importance than BP reduction per se [21, 22]. 
We previously noted [23] that left ventricular diastolic 
dysfunction coexists with subclinical left ventricular 
systolic dysfunction as measured by global longitudinal 
strain (GLS). Improvement in left ventricular diastolic 
function correlated significantly with improvement in GLS 
(GLS vs. e’: r = –0.51, p < 0.001; GLS vs. E/e’: r = 0.23, 
p = 0.022) [24]. This explains why diastolic dysfunction 
at rest may be a harbinger of more severe hemodynamic 
disturbance associated with exercise. Palmieri et al. [2] 
examined this phenomenon and showed an association 
between diastolic dysfunction and impaired increase in CI 
and SI during exercise, which reduces exercise capacity 
in still asymptomatic patients.
The observed trend for an increase in TFC related 
to increased 6-MWT distance should not be interpreted 
as a positive effect of fluid retention. Previous studies 
in this population [25, 26] suggest that among middle-
-aged subjects with uncomplicated HTN, baseline TFC 
may be reduced compensatory to increased afterload. 
Thus afterload reduction secondary to BP lowering may 
result in an increase in TFC due to normalization of the 
hemodynamic profile.
When interpreting our study findings, it is important to 
consider potential factors affecting the change in 6-MWT 
distance independently from the body’s functional status. 
In our opinion, contribution of the „learning effect” seen at 
2 months of follow-up [27, 28] was marginal. First, 6-MWT 
distance was re-evaluated at 12 months of treatment. 
Second, individual effects varied, and changes in many 
patients were larger than the previously reported 6% 
change attributed to this phenomenon [27, 28]. In turn, 
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Streszczenie
Wstęp. Indywidualne zróżnicowanie tolerancji wysiłku fizycznego może mieć istotne znaczenie kliniczne już pacjentów 
z nadciśnieniem tętniczym (HTN) bez objawów. Celem pracy była ocena wpływu terapii hipotensyjnej na zdolność do 
wykonania wysiłku ocenianą w teście 6-minutowego marszu (6-MWT) oraz powiązania tego efektu z wybranymi parame-
trami klinicznymi i hemodynamicznymi.
Materiał i metody. W grupie 111 chorych z HTN i bez jawnych objawów niewydolności serca oceniono zmianę dystan-
su 6-MWT (d_6-MWT) po 12 miesiącach od rozpoczęcia leczenia hipotensyjnego w powiązaniu ze stanem klinicznym 
oraz parametrami hemodynamicznymi uzyskanymi za pomocą echokardiografii, kardiografii impedancyjnej i tonometrii 
aplanacyjnej.
Wyniki. W analizie w całej grupie leczenie hipotensyjne wiązało się z istotnym wydłużeniem średniego dystansu 6-MWT: 
592,9 ± 72,8 v. 613,4 ± 66,0 m; p = 0,030. Zmiana dystansu 6-MWT zależała od wartości wyjściowych. Najwyraźniejszą 
poprawę zaobserwowano wśród chorych, którzy wyjściowo pokonali najkrótszy dystans 6-MWT (dolny kwartyl 6-MWT 
< 530 m), tj. 63,4 m. Nie wykazano istotnych statystycznie powiązań d_6-MWT ze zmianami analizowanych parame-
trów klinicznych i hemodynamicznych, choć obserwowano oczekiwany trend w kierunku pozytywnej korelacji d_6-MWT 
z obniżeniem echokardiograficznego wskaźnika ciśnienia napełniania (E/e’) oraz zwiększeniem frakcji wyrzutowej lewej 
komory i kardioimpedancyjnego wskaźnika wyrzutowego.
Wnioski. Leczenie hipotensyjne poprawia tolerancję wysiłku fizycznego u pacjentów z niższą wydolnością fizyczną, co 
może się wiązać z poprawą funkcji skurczowej i rozkurczowej lewej komory.
Słowa kluczowe: kardiografia impedancyjna, tonometria aplanacyjna, nadciśnienie tętnicze, dysfunkcja rozkurczowa 
lewej komory, test 6-minutowego marszu
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